| Fair Value, by Balance Sheet Grouping [Table Text Block] |
The valuation methodologies used for the Company's financial instruments measured on a recurring basis at fair value, including the general classification of such instruments pursuant to the valuation hierarchy, is set forth in the tables below.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of December 31, 2014 |
|
Fair Value Measurements |
|
Carrying |
|
Fair |
|
As of December 31, 2014 |
|
Amount |
|
Value |
|
Level 1 |
|
Level 2 |
|
Level 3 |
Assets: |
|
|
|
|
|
|
|
|
|
Cash and cash equivalents: |
|
|
|
|
|
|
|
|
|
Cash |
$ |
6,836 |
|
|
$ |
6,836 |
|
|
$ |
6,836 |
|
|
$ |
— |
|
|
$ |
— |
|
Money market funds |
16,275 |
|
|
16,275 |
|
|
16,275 |
|
|
— |
|
|
— |
|
|
$ |
23,111 |
|
|
$ |
23,111 |
|
|
$ |
23,111 |
|
|
$ |
— |
|
|
$ |
— |
|
Marketable securities: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Money market funds |
$ |
48 |
|
|
$ |
48 |
|
|
$ |
48 |
|
|
$ |
— |
|
|
$ |
— |
|
Mutual funds |
59 |
|
|
59 |
|
|
59 |
|
|
— |
|
|
— |
|
U.S. Treasury securities |
1,070 |
|
|
1,070 |
|
|
1,070 |
|
|
— |
|
|
— |
|
Government agency securities |
317 |
|
|
317 |
|
|
317 |
|
|
— |
|
|
— |
|
|
$ |
1,494 |
|
|
$ |
1,494 |
|
|
$ |
1,494 |
|
|
$ |
— |
|
|
$ |
— |
|
Liabilities: |
|
|
|
|
|
|
|
|
|
Contingent consideration: |
|
|
|
|
|
|
|
|
|
Asuragen |
$ |
4,476 |
|
|
$ |
4,476 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
4,476 |
|
RedPath |
22,066 |
|
|
22,066 |
|
|
— |
|
|
— |
|
|
22,066 |
|
|
$ |
26,542 |
|
|
$ |
26,542 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
26,542 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of December 31, 2013 |
|
Fair Value Measurements |
|
Carrying |
|
Fair |
|
As of December 31, 2013 |
|
Amount |
|
Value |
|
Level 1 |
|
Level 2 |
|
Level 3 |
Assets: |
|
|
|
|
|
|
|
|
|
Cash and cash equivalents: |
|
|
|
|
|
|
|
|
|
Cash |
$ |
10,315 |
|
|
$ |
10,315 |
|
|
$ |
10,315 |
|
|
$ |
— |
|
|
$ |
— |
|
Money market funds |
35,324 |
|
|
35,324 |
|
|
35,324 |
|
|
— |
|
|
— |
|
|
$ |
45,639 |
|
|
$ |
45,639 |
|
|
$ |
45,639 |
|
|
$ |
— |
|
|
$ |
— |
|
Marketable securities: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Money market funds |
$ |
48 |
|
|
$ |
48 |
|
|
$ |
48 |
|
|
$ |
— |
|
|
$ |
— |
|
Mutual funds |
55 |
|
|
55 |
|
|
55 |
|
|
— |
|
|
— |
|
U.S. Treasury securities |
1,730 |
|
|
1,730 |
|
|
1,730 |
|
|
— |
|
|
— |
|
Government agency securities |
382 |
|
|
382 |
|
|
382 |
|
|
— |
|
|
— |
|
|
$ |
2,215 |
|
|
$ |
2,215 |
|
|
$ |
2,215 |
|
|
$ |
— |
|
|
$ |
— |
|
|
|
| Fair Value Measurements, Nonrecurring [Table Text Block] |
The following table summarizes these assets of the Company measured at fair value on a nonrecurring basis as of December 31, 2014:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair Value Measurements as of |
|
|
Carrying Amount as of |
|
December 31, 2014 |
|
|
December 31, 2014 |
|
Level 1 |
|
Level 2 |
|
Level 3 |
Long-lived assets held and used: |
|
|
|
|
|
|
|
|
Thyroid |
|
$ |
522 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
522 |
|
Pancreas |
|
8,519 |
|
|
— |
|
|
— |
|
|
8,519 |
|
Biobank |
|
2,728 |
|
|
— |
|
|
— |
|
|
2,728 |
|
Pancreas test |
|
1,428 |
|
|
— |
|
|
— |
|
|
1,428 |
|
Barrett's test |
|
15,756 |
|
|
— |
|
|
— |
|
|
15,756 |
|
CLIA lab |
|
18,351 |
|
|
— |
|
|
— |
|
|
18,351 |
|
|
|
$ |
47,304 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
47,304 |
|
|
|